141 Results for 'Drug Development'
DNA Nanostructures for Drug Delivery
Researchers at the Wyss Institute have developed two methods for building arbitrarily shaped nanostructures using DNA, with a focus on translating the technology towards nanofabrication and drug delivery applications. One proprietary nanofabrication technique, called “DNA-brick self-assembly,” uses short, synthetic strands of DNA that work like interlocking Lego® bricks. It capitalizes on the ability to program...
Fluorescent In Situ Sequencing (FISSEQ)
Working copies of active genes — called messenger RNAs or mRNAs —translate the genetic information present in DNA into proteins within the cells’ multiple compartments. They are often positioned strategically within cells in ways that contribute critically to how cells and tissues grow, develop and function, and their mislocation can lead to disease development. To...
Putting Biofilms to Work
A team at the Wyss Institute sees biofilms as a robust new platform for designer nanomaterials that could treat inflammatory bowel diseases, clean up polluted rivers, manufacture pharmaceutical products, fabricate new textiles, and more. A novel protein engineering system called BIND, which stands for Biofilm-Integrated Nanofiber Display, could be the essential ingredient in tomorrow’s probiotic...
Implantable cancer vaccine
The Wyss Institute’s implantable, biodegradable cancer vaccine leverages immunotherapeutic methods and could one day help overcome melanoma, other cancers, infectious diseases, auto-immune diseases, as well as vaccinate against specific peptides, proteins, or antigens. The implant is a biodegradable polymer scaffold containing growth factors and components of each patient’s tumors. The technology was initially designed to...
Mechanically-Activated Drug Targeting Nanotechnology
The Wyss team has developed a novel drug targeting nanotechnology that is activated locally by mechanical forces, either endogenous high shear stresses in blood created by vascular occlusion or mechanical energy applied locally using low-energy ultrasound radiation. Today, vascular blockage is the leading cause of death and disability in United States and Europe. Current therapies...
Clinical studies take years to complete and testing a single compound can cost more than $2 billion. Meanwhile, innumerable animal lives are lost, and the process often fails to predict human responses because traditional animal models often do not accurately mimic human pathophysiology. For these reasons, there is a broad need for alternative ways to...
Dec 13 → Dec 15, 2016
- Add to Calendar
- Google Calendar
Computational tools have the ability to add tangible value to the development of biologic drugs. When utilized effectively, computational techniques can shorten timelines and enhance the cost-effectiveness of biologic drug development. Computational Drug Development 2016 will bridge the gap between the application of computational tools for small molecule and biologic drug development. This meeting will...
Oct 20, 2016, 6:00pm - 7:45pm
- Add to Calendar
- Google Calendar
Disruption in biotech can come in different forms, from new technologies that can change the face of medicine, to ideas and initiatives that can challenge the status quo. Boston has both of these in spades, with ambitious biotech startups bent on transforming drug development and industry leaders unafraid to tackle the sector’s toughest issues. But...